[
    {
        "molecule_name": "LAG-3 antibody or binding fragment thereof",
        "protein_target_name": "human LAG-3 extracellular domain monomer",
        "binding_metric": "EC50",
        "value": "<0.5",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain monomer (-his tagged monomer), preferably, EC50 is less than 0.5nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular region dimer monomer (-Fc tagged dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 monomers (-his taggeddhlag 3-D12 monomer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 dimer (-Fctagged hLAG3-D12 dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the binding activity of the LAG-3 antibody or binding fragment thereof to the extracellular domain of cynomolgus monkey (cynomolgus) LAG-3 is weaker than the binding activity to the extracellular domain of human LAG-3 by more than 100-fold as measured by ELISA for EC 50.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has weak binding activity to the extracellular region of cynomolgus monkey (cynomolgus) LAG-3, and the KD is measured by Biacore at 10<sup>-8</sup>M is more than M.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the affinity (Biacore assay KD) of the LAG-3 antibody or binding fragment thereof to human LAG-3 is strong, preferably with a KD of 10<sup>-9</sup>M range or lower."
    },
    {
        "molecule_name": "LAG-3 antibody or binding fragment thereof",
        "protein_target_name": "human LAG-3 extracellular region dimer monomer",
        "binding_metric": "EC50",
        "value": "<1",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain monomer (-his tagged monomer), preferably, EC50 is less than 0.5nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular region dimer monomer (-Fc tagged dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 monomers (-his taggeddhlag 3-D12 monomer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 dimer (-Fctagged hLAG3-D12 dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the binding activity of the LAG-3 antibody or binding fragment thereof to the extracellular domain of cynomolgus monkey (cynomolgus) LAG-3 is weaker than the binding activity to the extracellular domain of human LAG-3 by more than 100-fold as measured by ELISA for EC 50.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has weak binding activity to the extracellular region of cynomolgus monkey (cynomolgus) LAG-3, and the KD is measured by Biacore at 10<sup>-8</sup>M is more than M.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the affinity (Biacore assay KD) of the LAG-3 antibody or binding fragment thereof to human LAG-3 is strong, preferably with a KD of 10<sup>-9</sup>M range or lower."
    },
    {
        "molecule_name": "LAG-3 antibody or binding fragment thereof",
        "protein_target_name": "human LAG-3 extracellular domain 1 and 2 monomers",
        "binding_metric": "EC50",
        "value": "<1",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain monomer (-his tagged monomer), preferably, EC50 is less than 0.5nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular region dimer monomer (-Fc tagged dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 monomers (-his taggeddhlag 3-D12 monomer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 dimer (-Fctagged hLAG3-D12 dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the binding activity of the LAG-3 antibody or binding fragment thereof to the extracellular domain of cynomolgus monkey (cynomolgus) LAG-3 is weaker than the binding activity to the extracellular domain of human LAG-3 by more than 100-fold as measured by ELISA for EC 50.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has weak binding activity to the extracellular region of cynomolgus monkey (cynomolgus) LAG-3, and the KD is measured by Biacore at 10<sup>-8</sup>M is more than M.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the affinity (Biacore assay KD) of the LAG-3 antibody or binding fragment thereof to human LAG-3 is strong, preferably with a KD of 10<sup>-9</sup>M range or lower."
    },
    {
        "molecule_name": "LAG-3 antibody or binding fragment thereof",
        "protein_target_name": "human LAG-3 extracellular domain 1 and 2 dimer",
        "binding_metric": "EC50",
        "value": "<1",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain monomer (-his tagged monomer), preferably, EC50 is less than 0.5nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular region dimer monomer (-Fc tagged dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 monomers (-his taggeddhlag 3-D12 monomer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 dimer (-Fctagged hLAG3-D12 dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the binding activity of the LAG-3 antibody or binding fragment thereof to the extracellular domain of cynomolgus monkey (cynomolgus) LAG-3 is weaker than the binding activity to the extracellular domain of human LAG-3 by more than 100-fold as measured by ELISA for EC 50.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has weak binding activity to the extracellular region of cynomolgus monkey (cynomolgus) LAG-3, and the KD is measured by Biacore at 10<sup>-8</sup>M is more than M.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the affinity (Biacore assay KD) of the LAG-3 antibody or binding fragment thereof to human LAG-3 is strong, preferably with a KD of 10<sup>-9</sup>M range or lower."
    },
    {
        "molecule_name": "LAG-3 antibody or binding fragment thereof",
        "protein_target_name": "cynomolgus monkey LAG-3",
        "binding_metric": "KD",
        "value": "10^-8",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain monomer (-his tagged monomer), preferably, EC50 is less than 0.5nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular region dimer monomer (-Fc tagged dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 monomers (-his taggeddhlag 3-D12 monomer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 dimer (-Fctagged hLAG3-D12 dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the binding activity of the LAG-3 antibody or binding fragment thereof to the extracellular domain of cynomolgus monkey (cynomolgus) LAG-3 is weaker than the binding activity to the extracellular domain of human LAG-3 by more than 100-fold as measured by ELISA for EC 50.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has weak binding activity to the extracellular region of cynomolgus monkey (cynomolgus) LAG-3, and the KD is measured by Biacore at 10<sup>-8</sup>M is more than M.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the affinity (Biacore assay KD) of the LAG-3 antibody or binding fragment thereof to human LAG-3 is strong, preferably with a KD of 10<sup>-9</sup>M range or lower."
    },
    {
        "molecule_name": "LAG-3 antibody or binding fragment thereof",
        "protein_target_name": "human LAG-3",
        "binding_metric": "KD",
        "value": "10^-9",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain monomer (-his tagged monomer), preferably, EC50 is less than 0.5nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular region dimer monomer (-Fc tagged dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 monomers (-his taggeddhlag 3-D12 monomer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has strong binding activity to human LAG-3 extracellular domain 1 and 2 dimer (-Fctagged hLAG3-D12 dimer), preferably with an EC50 of less than 1nM as measured by ELISA.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the binding activity of the LAG-3 antibody or binding fragment thereof to the extracellular domain of cynomolgus monkey (cynomolgus) LAG-3 is weaker than the binding activity to the extracellular domain of human LAG-3 by more than 100-fold as measured by ELISA for EC 50.\nIn a preferred embodiment of the present invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the LAG-3 antibody or binding fragment thereof has weak binding activity to the extracellular region of cynomolgus monkey (cynomolgus) LAG-3, and the KD is measured by Biacore at 10<sup>-8</sup>M is more than M.\nIn a preferred embodiment of the invention, there is provided a LAG-3 antibody or binding fragment thereof as described above, wherein the affinity (Biacore assay KD) of the LAG-3 antibody or binding fragment thereof to human LAG-3 is strong, preferably with a KD of 10<sup>-9</sup>M range or lower."
    },
    {
        "molecule_name": "hLAG-3",
        "protein_target_name": "human LAG-3 recombinant protein",
        "binding_metric": "EC50",
        "value": "<5 times better than positive control antibody Ref",
        "unit": null,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe concentration gradient of the antigen LAG-3-his was 0nM, 1.875nM, 3.75nM, 7.5nM, 15nM, and 30nM, \nThe invention uses human LAG-3 recombinant protein as antigen, immunizes mouse, screens fusion hybridoma, screens and optimizes from millions of hybridoma clones, and unexpectedly discovers two hybridoma cell strains with very good hLAG-3 binding activity (EC 50 is 5 times better than positive control antibody Ref). \nThe experimental data were fitted with a 1:1Langmuir model using Biacore T200 evaluation version 3.0 (GE) software to give an affinity value KD. \nand clones with high binding activity were selected based on OD values or EC50 values (for antibodies of known concentration) were calculated."
    },
    {
        "molecule_name": "mab7c",
        "protein_target_name": "hLAG-3",
        "binding_metric": "IC50",
        "value": "0.58",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nmab7c\t0.14\tnM\nmab12c\t0.25\tnM\nRef\t0.84\tnM\nmab7c\t0.58\tnM\nmab12c\t0.79\tnM\nRef\t1.5\tnM\nThe EC50 of mab7c and mab12c of the present invention are 0.14 and 0.25 nM, respectively.\nEC50= 0.84nM for positive control molecules (Ref) under the same experiment.\nThe binding activity of mab7c, mab12c on hLAG-3 and daudi cells (MHCII) was tested using the method of example 4 and the two antibody activities were found to be IC50 between 0.58 and 0.79 nM, more than 1-fold stronger than the control (IC50 =1.5 nM)."
    },
    {
        "molecule_name": "mab12c",
        "protein_target_name": "hLAG-3",
        "binding_metric": "IC50",
        "value": "0.79",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nmab7c\t0.14\tnM\nmab12c\t0.25\tnM\nRef\t0.84\tnM\nmab7c\t0.58\tnM\nmab12c\t0.79\tnM\nRef\t1.5\tnM\nThe EC50 of mab7c and mab12c of the present invention are 0.14 and 0.25 nM, respectively.\nEC50= 0.84nM for positive control molecules (Ref) under the same experiment.\nThe binding activity of mab7c, mab12c on hLAG-3 and daudi cells (MHCII) was tested using the method of example 4 and the two antibody activities were found to be IC50 between 0.58 and 0.79 nM, more than 1-fold stronger than the control (IC50 =1.5 nM)."
    },
    {
        "molecule_name": "mab7c",
        "protein_target_name": "hLAG-3",
        "binding_metric": "EC50",
        "value": "0.14",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nmab7c\t0.14\tnM\nmab12c\t0.25\tnM\nRef\t0.84\tnM\nmab7c\t0.58\tnM\nmab12c\t0.79\tnM\nRef\t1.5\tnM\nThe EC50 of mab7c and mab12c of the present invention are 0.14 and 0.25 nM, respectively.\nEC50= 0.84nM for positive control molecules (Ref) under the same experiment.\nThe binding activity of mab7c, mab12c on hLAG-3 and daudi cells (MHCII) was tested using the method of example 4 and the two antibody activities were found to be IC50 between 0.58 and 0.79 nM, more than 1-fold stronger than the control (IC50 =1.5 nM)."
    },
    {
        "molecule_name": "mab12c",
        "protein_target_name": "hLAG-3",
        "binding_metric": "EC50",
        "value": "0.25",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nmab7c\t0.14\tnM\nmab12c\t0.25\tnM\nRef\t0.84\tnM\nmab7c\t0.58\tnM\nmab12c\t0.79\tnM\nRef\t1.5\tnM\nThe EC50 of mab7c and mab12c of the present invention are 0.14 and 0.25 nM, respectively.\nEC50= 0.84nM for positive control molecules (Ref) under the same experiment.\nThe binding activity of mab7c, mab12c on hLAG-3 and daudi cells (MHCII) was tested using the method of example 4 and the two antibody activities were found to be IC50 between 0.58 and 0.79 nM, more than 1-fold stronger than the control (IC50 =1.5 nM)."
    },
    {
        "molecule_name": "Ab835",
        "protein_target_name": "hLAG-3",
        "binding_metric": "EC50",
        "value": "0.41",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThe above results indicate that mab7c, mab12c, the murine chimeric antibody of the invention, binds 3-5 times more actively than the control molecule, and that Ab812, Ab813, which consists of the light chain of mab7c and the heavy chain of mab12c, the heavy chain of mab7c and the light chain of mab12c, show the same binding activity with EC50 of 0.15 and 0.17nM, respectively.\nFurthermore, the binding activity of these preferred antibodies is more than 5-fold stronger than the control antibody Ref, see table above (Ab 835 EC50=0.12 nM vs Ref E50 =0.77 nM), or fig. 2 a.\nFig. 2b shows that Ab835 and hLAG-3 positive cells have a binding activity EC50= 0.41nM, which is 4-fold stronger than the binding activity EC50=2.3 nM of the positive molecule Ref."
    },
    {
        "molecule_name": "Ref",
        "protein_target_name": "hLAG-3",
        "binding_metric": "EC50",
        "value": "2.3",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThe above results indicate that mab7c, mab12c, the murine chimeric antibody of the invention, binds 3-5 times more actively than the control molecule, and that Ab812, Ab813, which consists of the light chain of mab7c and the heavy chain of mab12c, the heavy chain of mab7c and the light chain of mab12c, show the same binding activity with EC50 of 0.15 and 0.17nM, respectively.\nFurthermore, the binding activity of these preferred antibodies is more than 5-fold stronger than the control antibody Ref, see table above (Ab 835 EC50=0.12 nM vs Ref E50 =0.77 nM), or fig. 2 a.\nFig. 2b shows that Ab835 and hLAG-3 positive cells have a binding activity EC50= 0.41nM, which is 4-fold stronger than the binding activity EC50=2.3 nM of the positive molecule Ref."
    },
    {
        "molecule_name": "Ab835",
        "protein_target_name": "human LAG-3",
        "binding_metric": "KD",
        "value": "0.52",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAb835 \n0.12 \n0.59 \n0.6 \n0.8 \n350 \nND#\n39 \n\nRef \n0.58 \n2.4 \n4.6 \n3.2 \n25 \n12.0 \n47 \n\nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. \nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. In particular, the antibodies of the invention block binding of MHCII and human LAG-3 with IC50 ab835= 2.27nM vs Ref = 2.76nM (fig. 3 a), and their functional activity preventing binding of LAG-3 and MHCII to activate human T cell activity (release of IL 2) EC50 ab835=1.74ug/ml vs Ref =1.56 ug/ml (fig. 3b) is at least comparable to that of clinical molecules (control Ref).\nTABLE 11 Biacore affinity analysis of the antibody Ab835 of the present invention\nAntibodies\nAntigens\nKa(1/ms)\nKd(1/s)\nKD (nM)\nAb835\nHuman LAG-3-his\n4.02E+06\n2.07E-03\n0.52"
    },
    {
        "molecule_name": "Ab835",
        "protein_target_name": "human LAG-3",
        "binding_metric": "IC50",
        "value": "2.27",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAb835 \n0.12 \n0.59 \n0.6 \n0.8 \n350 \nND#\n39 \n\nRef \n0.58 \n2.4 \n4.6 \n3.2 \n25 \n12.0 \n47 \n\nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. \nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. In particular, the antibodies of the invention block binding of MHCII and human LAG-3 with IC50 ab835= 2.27nM vs Ref = 2.76nM (fig. 3 a), and their functional activity preventing binding of LAG-3 and MHCII to activate human T cell activity (release of IL 2) EC50 ab835=1.74ug/ml vs Ref =1.56 ug/ml (fig. 3b) is at least comparable to that of clinical molecules (control Ref).\nTABLE 11 Biacore affinity analysis of the antibody Ab835 of the present invention\nAntibodies\nAntigens\nKa(1/ms)\nKd(1/s)\nKD (nM)\nAb835\nHuman LAG-3-his\n4.02E+06\n2.07E-03\n0.52"
    },
    {
        "molecule_name": "Ref",
        "protein_target_name": "human LAG-3",
        "binding_metric": "IC50",
        "value": "2.76",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAb835 \n0.12 \n0.59 \n0.6 \n0.8 \n350 \nND#\n39 \n\nRef \n0.58 \n2.4 \n4.6 \n3.2 \n25 \n12.0 \n47 \n\nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. \nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. In particular, the antibodies of the invention block binding of MHCII and human LAG-3 with IC50 ab835= 2.27nM vs Ref = 2.76nM (fig. 3 a), and their functional activity preventing binding of LAG-3 and MHCII to activate human T cell activity (release of IL 2) EC50 ab835=1.74ug/ml vs Ref =1.56 ug/ml (fig. 3b) is at least comparable to that of clinical molecules (control Ref).\nTABLE 11 Biacore affinity analysis of the antibody Ab835 of the present invention\nAntibodies\nAntigens\nKa(1/ms)\nKd(1/s)\nKD (nM)\nAb835\nHuman LAG-3-his\n4.02E+06\n2.07E-03\n0.52"
    },
    {
        "molecule_name": "Ab835",
        "protein_target_name": "human LAG-3",
        "binding_metric": "EC50",
        "value": "1.74",
        "unit": "ug/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAb835 \n0.12 \n0.59 \n0.6 \n0.8 \n350 \nND#\n39 \n\nRef \n0.58 \n2.4 \n4.6 \n3.2 \n25 \n12.0 \n47 \n\nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. \nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. In particular, the antibodies of the invention block binding of MHCII and human LAG-3 with IC50 ab835= 2.27nM vs Ref = 2.76nM (fig. 3 a), and their functional activity preventing binding of LAG-3 and MHCII to activate human T cell activity (release of IL 2) EC50 ab835=1.74ug/ml vs Ref =1.56 ug/ml (fig. 3b) is at least comparable to that of clinical molecules (control Ref).\nTABLE 11 Biacore affinity analysis of the antibody Ab835 of the present invention\nAntibodies\nAntigens\nKa(1/ms)\nKd(1/s)\nKD (nM)\nAb835\nHuman LAG-3-his\n4.02E+06\n2.07E-03\n0.52"
    },
    {
        "molecule_name": "Ref",
        "protein_target_name": "human LAG-3",
        "binding_metric": "EC50",
        "value": "1.56",
        "unit": "ug/ml",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAb835 \n0.12 \n0.59 \n0.6 \n0.8 \n350 \nND#\n39 \n\nRef \n0.58 \n2.4 \n4.6 \n3.2 \n25 \n12.0 \n47 \n\nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. \nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. In particular, the antibodies of the invention block binding of MHCII and human LAG-3 with IC50 ab835= 2.27nM vs Ref = 2.76nM (fig. 3 a), and their functional activity preventing binding of LAG-3 and MHCII to activate human T cell activity (release of IL 2) EC50 ab835=1.74ug/ml vs Ref =1.56 ug/ml (fig. 3b) is at least comparable to that of clinical molecules (control Ref).\nTABLE 11 Biacore affinity analysis of the antibody Ab835 of the present invention\nAntibodies\nAntigens\nKa(1/ms)\nKd(1/s)\nKD (nM)\nAb835\nHuman LAG-3-his\n4.02E+06\n2.07E-03\n0.52"
    },
    {
        "molecule_name": "Ab835",
        "protein_target_name": "human LAG-3-his",
        "binding_metric": "Ka",
        "value": "4.02E+06",
        "unit": "1/ms",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAb835 \n0.12 \n0.59 \n0.6 \n0.8 \n350 \nND#\n39 \n\nRef \n0.58 \n2.4 \n4.6 \n3.2 \n25 \n12.0 \n47 \n\nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. \nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. In particular, the antibodies of the invention block binding of MHCII and human LAG-3 with IC50 ab835= 2.27nM vs Ref = 2.76nM (fig. 3 a), and their functional activity preventing binding of LAG-3 and MHCII to activate human T cell activity (release of IL 2) EC50 ab835=1.74ug/ml vs Ref =1.56 ug/ml (fig. 3b) is at least comparable to that of clinical molecules (control Ref).\nTABLE 11 Biacore affinity analysis of the antibody Ab835 of the present invention\nAntibodies\nAntigens\nKa(1/ms)\nKd(1/s)\nKD (nM)\nAb835\nHuman LAG-3-his\n4.02E+06\n2.07E-03\n0.52"
    },
    {
        "molecule_name": "Ab835",
        "protein_target_name": "human LAG-3-his",
        "binding_metric": "Kd",
        "value": "2.07E-03",
        "unit": "1/s",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAb835 \n0.12 \n0.59 \n0.6 \n0.8 \n350 \nND#\n39 \n\nRef \n0.58 \n2.4 \n4.6 \n3.2 \n25 \n12.0 \n47 \n\nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. \nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. In particular, the antibodies of the invention block binding of MHCII and human LAG-3 with IC50 ab835= 2.27nM vs Ref = 2.76nM (fig. 3 a), and their functional activity preventing binding of LAG-3 and MHCII to activate human T cell activity (release of IL 2) EC50 ab835=1.74ug/ml vs Ref =1.56 ug/ml (fig. 3b) is at least comparable to that of clinical molecules (control Ref).\nTABLE 11 Biacore affinity analysis of the antibody Ab835 of the present invention\nAntibodies\nAntigens\nKa(1/ms)\nKd(1/s)\nKD (nM)\nAb835\nHuman LAG-3-his\n4.02E+06\n2.07E-03\n0.52"
    },
    {
        "molecule_name": "Ab835",
        "protein_target_name": "human LAG-3-his",
        "binding_metric": "KD",
        "value": "0.52",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nAb835 \n0.12 \n0.59 \n0.6 \n0.8 \n350 \nND#\n39 \n\nRef \n0.58 \n2.4 \n4.6 \n3.2 \n25 \n12.0 \n47 \n\nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. \nThe results in Table 11 show that the binding constant (Ka), dissociation constant (Kd), and affinity KD (0.52 nM) of the anti-human LAG-3 antibodies of the invention and the specific antigen human LAG-3 are within the appropriate range required for a suitable therapeutic antibody drug. In particular, the antibodies of the invention block binding of MHCII and human LAG-3 with IC50 ab835= 2.27nM vs Ref = 2.76nM (fig. 3 a), and their functional activity preventing binding of LAG-3 and MHCII to activate human T cell activity (release of IL 2) EC50 ab835=1.74ug/ml vs Ref =1.56 ug/ml (fig. 3b) is at least comparable to that of clinical molecules (control Ref).\nTABLE 11 Biacore affinity analysis of the antibody Ab835 of the present invention\nAntibodies\nAntigens\nKa(1/ms)\nKd(1/s)\nKD (nM)\nAb835\nHuman LAG-3-his\n4.02E+06\n2.07E-03\n0.52"
    }
]